ERAXIS Drug Patent Profile
✉ Email this page to a colleague
When do Eraxis patents expire, and when can generic versions of Eraxis launch?
Eraxis is a drug marketed by Vicuron Holdings and is included in one NDA.
The generic ingredient in ERAXIS is anidulafungin. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the anidulafungin profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ERAXIS?
- What are the global sales for ERAXIS?
- What is Average Wholesale Price for ERAXIS?
Summary for ERAXIS
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 56 |
| Clinical Trials: | 11 |
| Patent Applications: | 3,160 |
| Drug Prices: | Drug price information for ERAXIS |
| What excipients (inactive ingredients) are in ERAXIS? | ERAXIS excipients list |
| DailyMed Link: | ERAXIS at DailyMed |
Recent Clinical Trials for ERAXIS
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Center for Research Resources (NCRR) | Phase 4 |
| Texas Tech University Health Sciences Center | Phase 4 |
| University of Texas Southwestern Medical Center | Phase 4 |
Pharmacology for ERAXIS
| Drug Class | Echinocandin Antifungal |
US Patents and Regulatory Information for ERAXIS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vicuron Holdings | ERAXIS | anidulafungin | POWDER;INTRAVENOUS | 021632-001 | Feb 17, 2006 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Vicuron Holdings | ERAXIS | anidulafungin | POWDER;INTRAVENOUS | 021632-002 | Nov 14, 2006 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ERAXIS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Vicuron Holdings | ERAXIS | anidulafungin | POWDER;INTRAVENOUS | 021632-002 | Nov 14, 2006 | ⤷ Sign Up | ⤷ Sign Up |
| Vicuron Holdings | ERAXIS | anidulafungin | POWDER;INTRAVENOUS | 021632-001 | Feb 17, 2006 | ⤷ Sign Up | ⤷ Sign Up |
| Vicuron Holdings | ERAXIS | anidulafungin | POWDER;INTRAVENOUS | 021632-001 | Feb 17, 2006 | ⤷ Sign Up | ⤷ Sign Up |
| Vicuron Holdings | ERAXIS | anidulafungin | POWDER;INTRAVENOUS | 021632-002 | Nov 14, 2006 | ⤷ Sign Up | ⤷ Sign Up |
| Vicuron Holdings | ERAXIS | anidulafungin | POWDER;INTRAVENOUS | 021632-002 | Nov 14, 2006 | ⤷ Sign Up | ⤷ Sign Up |
| Vicuron Holdings | ERAXIS | anidulafungin | POWDER;INTRAVENOUS | 021632-001 | Feb 17, 2006 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for ERAXIS
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Pfizer Europe MA EEIG | Ecalta | anidulafungin | EMEA/H/C/000788 Treatment of invasive candidiasis in adults and paediatric patients aged 1 month to < 18 years. |
Authorised | no | no | no | 2007-09-20 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for ERAXIS
See the table below for patents covering ERAXIS around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| European Patent Office | 0561639 | Dérivés cyclopeptidiques antifongiques et procédé de leur préparation (Cyclic peptide antifungal agents and process for preparation thereof) | ⤷ Sign Up |
| Taiwan | 200400831 | Antifungal parenteral products | ⤷ Sign Up |
| Finland | 931202 | ⤷ Sign Up | |
| Denmark | 0561639 | ⤷ Sign Up | |
| European Patent Office | 1511378 | PRODUITS PARENT RAUX ANTIFONGIQUES (ANTIFUNGAL PARENTERAL PRODUCTS) | ⤷ Sign Up |
| Hungary | 9300785 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ERAXIS
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0561639 | CA 2008 00017 | Denmark | ⤷ Sign Up | |
| 0561639 | SPC/GB08/016 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: ANIDULAFUNGIN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/07/416/001 20070920 |
| 0561639 | 300334 | Netherlands | ⤷ Sign Up | 300334, 20130318, EXPIRES: 20180317 |
| 0561639 | C00561639/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: ANIDULAFUNGIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 58325 03.09.2009 |
| 0561639 | SPC002/2008 | Ireland | ⤷ Sign Up | SPC002/2008: 20081105, EXPIRES: 20180317 |
| 0561639 | 08C0009 | France | ⤷ Sign Up | PRODUCT NAME: ANIDULAFUNGINE; REGISTRATION NO/DATE: EU/1/07/416/001 20070920 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
